← CVS HEALTH Corp

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $5.3b
$6.6b +24.54%
($594.0m) -108.97%
$6.6b +1216.84%
$7.2b +8.22%
$7.9b +10.18%
$4.1b -47.55%
$8.3b +101.11%
$4.6b -44.70%
$1.8b -61.68%
—
Net Income (Loss) Available to Common Stockholders, Basic $5.3b
$6.6b +24.52%
($596.0m) -109.00%
$6.6b +1212.58%
$7.2b +8.46%
$7.9b +9.82%
$4.2b -47.27%
$8.3b +100.34%
$4.6b -44.70%
$1.8b -61.68%
—
Net Income (Loss) Attributable to Noncontrolling Interest $2.0m $1.0m ($2.0m) ($3.0m) $13.0m ($12.0m) $16.0m $24.0m ($28.0m) ($40.0m) —
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $5.3b $6.6b ($596.0m) $6.6b $7.2b $7.9b $4.2b $8.4b $4.6b $1.7b —
Amortization of Intangible Assets $795.0m $817.0m $1.0b $2.4b $2.3b $2.3b $1.8b $1.9b $2.0b $2.0b —
Deferred Policy Acquisition Costs, Amortization Expense — — — — — — — $265.0m $299.0m $346.0m —
Depreciation $1.7b $1.7b $1.7b $1.9b $2.1b $2.3b $2.4b $2.5b $2.6b $2.6b $4.5b
Depreciation, Depletion and Amortization $2.5b $2.5b $2.7b $4.4b $4.4b $4.5b $4.2b $4.4b $4.6b $4.6b $4.5b
Deferred Income Tax Expense (Benefit) $3.0m ($1.4b) $23.0m ($649.0m) ($564.0m) ($428.0m) ($2.1b) ($676.0m) ($572.0m) $102.0m $144.0m
Deferred income taxes $18.0m ($1.3b) $87.0m ($654.0m) ($570.0m) ($428.0m) ($2.1b) ($676.0m) ($572.0m) $102.0m $144.0m
Payment, Tax Withholding, Share-based Payment Arrangement — $71.0m $97.0m $112.0m $88.0m $168.0m $370.0m $181.0m $185.0m $158.0m —
Share-based Payment Arrangement, Expense $222.0m $234.0m $280.0m $453.0m $400.0m $484.0m $447.0m $588.0m $540.0m $535.0m $715.0m
Share-based Payment Arrangement, Noncash Expense $222.0m $234.0m $280.0m $453.0m $400.0m $484.0m $447.0m $588.0m $540.0m $535.0m $715.0m
Stock-based compensation $222.0m $234.0m $280.0m $453.0m $400.0m $484.0m $447.0m $588.0m $540.0m $535.0m $715.0m
Goodwill impairment $0 $181.0m $6.1b $0 $0 $431.0m $0 $0 $0 $5.7b $5.7b
Goodwill, Impairment Loss — $181.0m $6.1b $0 $0 $431.0m $0 $0 $0 $5.7b $5.7b
Impairment of Intangible Assets, Finite-lived — — $0 — — — — — — — —
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) — — $0 $0 $0 $0 $0 $0 $0 $0 —
Restructuring Costs and Asset Impairment Charges — — — — — — $0 $507.0m $1.2b $0 —
Restructuring charges (impairment of long-lived assets) — — — — — — $0 $152.0m $840.0m $0 —
Other Nonoperating Income (Expense) — — $4.0m $124.0m $206.0m $182.0m $169.0m $88.0m $99.0m $112.0m —
Changes in operating assets and liabilities:
Accounts Receivable, Credit Loss Expense (Reversal) — — $256.0m $111.0m — — — — — — $108.0m
Accounts receivable, net ($243.0m) ($941.0m) ($1.1b) ($2.2b) ($1.5b) ($2.7b) ($3.0b) ($6.3b) ($1.3b) ($3.5b) $108.0m
Increase (Decrease) in Accounts Receivable $243.0m $941.0m $1.1b $2.2b $1.5b $2.7b $3.0b $6.3b $1.3b $3.5b $108.0m
Cash paid for inventory, prescriptions dispensed and health services rendered ($140.3b) ($146.5b) ($148.8b) ($149.7b) ($158.6b) ($165.8b) ($189.8b) ($208.8b) ($197.7b) ($216.5b) —
Increase (Decrease) in Inventories $742.0m $514.0m $1.2b $1.1b $973.0m ($735.0m) $1.4b ($1.2b) $102.0m $1.3b ($314.0m)
Inventories ($742.0m) ($514.0m) ($1.2b) ($1.1b) ($973.0m) $735.0m ($1.4b) $1.2b ($102.0m) ($1.3b) ($314.0m)
Accounts payable and pharmacy claims and discounts payable $2.2b $1.7b $2.5b $3.5b $2.8b $2.9b $4.3b $3.6b $2.3b $3.9b ($320.0m)
Increase (Decrease) in Accounts Payable $2.2b $1.7b $2.5b $3.5b $2.8b $2.9b $4.3b $3.6b $2.3b $3.9b ($320.0m)
Accrued capital expenditures $2.2b $1.9b $2.0b $2.5b $2.4b $2.5b $2.7b $3.0b $2.8b $2.8b —
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims — — — — — — — $86.0b $114.8b $125.3b —
Increase (Decrease) in Other Operating Assets $43.0m ($3.0m) — $614.0m ($364.0m) $3.0m $566.0m $510.0m $38.0m $2.6b —
Increase (Decrease) in Other Operating Liabilities $2.0m $38.0m $165.0m $1.5b $2.7b $2.9b $6.5b $1.5b ($3.5b) $2.0b —
Other ($5.0m) ($1.0m) $1.0m $0 ($27.0m) $155.0m ($79.0m) ($201.0m) $26.0m $0 —
Other assets ($43.0m) $3.0m ($3.0m) ($614.0m) $364.0m ($3.0m) ($566.0m) ($510.0m) ($38.0m) ($2.6b) —
Other liabilities $2.0m $38.0m $165.0m $1.5b $2.7b $2.9b $6.5b $1.5b ($3.5b) $2.0b —
Net Cash Provided by (Used in) Operating Activities $10.1b
$8.0b -20.48%
$8.9b +10.72%
$12.8b +44.93%
$15.9b +23.48%
$18.3b +15.13%
$16.2b -11.43%
$13.4b -17.01%
$9.1b -32.17%
$10.6b +16.82%
$14.8b +38.92%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $2.2b $1.9b $2.0b $2.5b $2.4b $2.5b $2.7b $3.0b $2.8b $2.8b ($3.0b)
Payments to Acquire Investments — — $692.0m $7.5b $9.6b $10.0b $7.7b $9.0b $15.2b $15.0b ($16.5b)
Proceeds from sales and maturities of investments $91.0m $61.0m $817.0m $7.0b $6.5b $7.2b $6.7b $7.7b $10.4b $12.4b —
Purchases of investments ($80.0m) ($137.0m) ($692.0m) ($7.5b) ($9.6b) ($10.0b) ($7.7b) ($9.0b) ($15.2b) ($15.0b) —
Acquisitions (net of cash and restricted cash acquired) ($539.0m) ($1.3b) ($42.2b) ($444.0m) ($866.0m) ($146.0m) ($139.0m) ($16.6b) ($95.0m) ($436.0m) —
Payments to Acquire Businesses, Net of Cash Acquired $539.0m $1.3b $42.2b $444.0m $866.0m $146.0m $139.0m $16.6b $95.0m $436.0m ($306.0m)
Payments for (Proceeds from) Other Investing Activities — — ($21.0m) ($42.0m) $0 ($122.0m) ($85.0m) ($68.0m) ($101.0m) ($26.0m) —
Net Cash Provided by (Used in) Investing Activities ($2.5b) ($2.9b) ($43.3b) ($3.3b) ($5.5b) ($5.3b) ($5.0b) ($20.9b) ($7.6b) ($5.9b) ($6.8b)
Cash flows from financing activities:
Commercial paper borrowings (repayments), net — — — — — $0 $0 $200.0m $1.9b ($2.1b) —
Gain (Loss) on Extinguishment of Debt ($643.0m) $0 $0 ($79.0m) ($1.4b) ($452.0m) $0 $0 $491.0m $0 —
Gain on early extinguishment of debt $643.0m $0 $0 $79.0m $1.4b $452.0m $0 $0 ($491.0m) $0 —
Proceeds from Issuance of Long-term Debt $3.5b $0 $44.3b $3.7b $10.0b $987.0m $0 $10.9b $7.9b $4.0b $3.0b
Repayments of Long-term Debt $5.9b $0 $5.5b $8.3b $15.6b $10.3b $4.2b $3.2b $4.8b $3.6b ($6.2b)
Payments for Repurchase of Common Stock $4.5b $4.4b $0 $0 $0 $0 $3.5b $2.0b $3.0b $0 —
Repurchase of common stock ($4.5b) ($4.4b) $0 $0 $0 $0 ($3.5b) ($2.0b) ($3.0b) $0 —
Dividends paid $2k $2k $2k $3k $3k $3k $3k $3k $3k $3k ($3.4b)
Payments of Dividends $2k $2k $2k $3k $3k $3k $3k $3k $3k $3k ($3.4b)
Payments for taxes related to net share settlement of equity awards ($72.0m) ($71.0m) ($97.0m) ($112.0m) ($88.0m) ($168.0m) ($370.0m) ($181.0m) ($185.0m) ($158.0m) —
Net Cash Provided by (Used in) Financing Activities ($6.7b)
($6.8b) -0.93%
$36.8b +645.39%
($7.8b) -121.32%
($8.2b) -3.89%
($11.4b) -39.25%
($10.5b) +7.40%
$2.7b +125.51%
($1.1b) -142.30%
($4.9b) -335.24%
($8.4b) -70.55%
Net increase (decrease) in cash, cash equivalents and restricted cash $912.0m ($1.6b) $2.4b $1.7b $2.2b $1.6b $614.0m ($4.8b) $359.0m ($172.0m) —
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $912.0m ($1.6b) $2.4b $1.7b $2.2b $1.6b $614.0m ($4.8b) $359.0m ($172.0m) $11.5b
Cash, cash equivalents and restricted cash at the beginning of the period $3.5b $1.9b $4.3b $6.0b $8.1b $12.7b $13.3b $8.5b $8.9b $8.7b —
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $912.0m ($1.6b) $4.3b $6.0b $8.1b $12.7b $13.3b $8.5b $8.9b $8.7b $11.5b
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $912.0m ($1.6b) ($4.0m) $0 $0 $1.6b $614.0m ($4.8b) $359.0m ($172.0m) —
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Additional Financial Items
Cash paid to other suppliers and employees ($15.6b) ($15.3b) ($17.2b) ($28.9b) ($29.8b) ($31.7b) ($32.7b) ($34.7b) ($38.8b) ($37.6b) —
Cash receipts from customers $172.3b $176.6b $186.5b $248.4b $264.3b $284.2b $313.7b $345.5b $358.0b $389.1b —
Deconsolidation, Gain (Loss), Amount — — — — — — — — — $483.0m —
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement — ($187.0m) $0 $0 — — — — — — —
Gain (Loss) Related to Litigation Settlement — — — — — — ($5.8b) $0 ($100.0m) — —
Gain (Loss) on Disposition of Business — — — $205.0m $269.0m $0 $475.0m $0 $0 ($236.0m) —
Gain on deconsolidation of subsidiary — — — — — — — $0 $0 ($483.0m) —
Goodwill $38.2b $38.5b $78.7b $79.7b $79.6b $79.1b $78.2b $91.3b $91.3b $85.5b $5.7b
Health care costs payable and other insurance liabilities ($19.0m) $0 ($471.0m) $320.0m ($231.0m) $169.0m $1.2b $394.0m $2.8b $16.0m —
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent $5.3b $6.6b ($597.0m) $6.6b $7.2b $7.9b $4.1b — — — —
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $5.3b $6.6b ($596.0m) $6.6b $7.2b $7.9b $4.2b — — — —
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest ($1.0m) ($8.0m) $0 $0 ($9.0m) $0 $0 — — — —
Income Tax Expense (Benefit) $3.3b $1.6b $2.0b $2.4b $2.6b $2.5b $1.5b $2.8b $1.6b $408.0m —
Income Taxes Paid, Net ($3.1b) $2.9b $2.4b $2.7b $2.9b $3.2b $4.1b $3.5b $1.7b $2.2b —
Insurance benefits paid ($2.2b) ($2.8b) ($7.1b) ($52.2b) ($55.1b) ($63.6b) ($69.7b) ($84.1b) ($109.5b) ($121.2b) —
Interest Expense Nonoperating — — — — — — — — $3.0b $3.1b —
Interest Paid, Excluding Capitalized Interest, Operating Activities ($1.1b) $1.1b $2.8b $3.0b $2.9b $2.5b $2.2b $2.4b $2.9b $3.0b —
Interest and investment income received $20.0m $21.0m $644.0m $955.0m $894.0m $743.0m $1.0b $1.6b $1.7b $2.0b —
Investment Income, Interest $20.0m $21.0m — — — — — — — — —
Loss on assets held for sale — — — — $0 $0 $2.5b $349.0m $0 $0 —
Loss on sale of subsidiary — $0 $86.0m $205.0m ($269.0m) $0 ($475.0m) $0 $0 $236.0m —
Operating Expenses $18.5b $19.0b — $33.5b — — — — — — —
Other items $135.0m $53.0m $339.0m $264.0m $72.0m ($390.0m) $332.0m $416.0m ($502.0m) ($336.0m) —
Proceeds from (Payments to) Noncontrolling Interests — — $0 — — — — — — — —
Proceeds from Stock Options Exercised $224.0m $329.0m $242.0m $210.0m $264.0m $549.0m $551.0m $277.0m $361.0m $394.0m —
Proceeds from exercise of stock options $224.0m $329.0m $242.0m $210.0m $264.0m $549.0m $551.0m $277.0m $361.0m $394.0m —
Proceeds from issuance of short-term loan — — — — — $0 $0 $5.0b $0 $0 —
Realized Investment Gains (Losses) — — $3.0m $199.0m $52.0m $176.0m ($320.0m) ($497.0m) $117.0m ($44.0m) —
Repayment of short-term loan — — — — — $0 $0 ($5.0b) $0 $0 —
Supplemental disclosure of cash flow information:

Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.